TO THE EDITOR
Leukemic and tumor cells can escape from allogeneic recognition by usual cytotoxic T cells because of the low expression level of HLA class I molecules. It has recently been shown that inhibitory natural killer cell receptors (NKRs) on not only NK cells but also T cells negatively regulate NK cell and T-cell functions through their binding to MHC class I molecules. 1 Inhibitory NKR-positive cells could attack target cells with decreased expression of HLA class I molecules. 2, 3 The C-type lectin superfamily inhibitory NKR CD94/NKG2A heterodimer recognizes an HLA-E that preferably bound to a peptide derived from the signal sequences of most HLA class I. 4 Therefore, CD94 can monitor the global status of HLA class I on the tumor and leukemic cells and induce cytolytic attack without inhibitory signal against HLA class I decreased target cells.
In our previous studies, we were able to expand CD94/ NKG2A-expressing CD8 þ cells with cytolytic activity from granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cells (G-PBMCs) derived from normal donors after stimulation with immobilized anti-CD3 mAb and IL-15. 5 In this study, we expanded CD94-expressing T cells from four different sources of blood mononuclear cells (BMCs) and then investigated characteristics of their cytolytic activities against patients' primary leukemic cells in order to develop a potential strategy for cell therapy for hematological malignancy.
Blood mononuclear cells (BMCs) were obtained from six normal donors' peripheral blood (PBMCs), from three donors' cord blood (CB), from three donors' apheresed peripheral blood without G-CSF mobilization for donor lymphocyte infusion (DLIs) and from four patients' apheresed peripheral blood with G-CSF mobilization after chemotherapy for auto PBSCT (autologous G-CSF-mobilized PBMCs, AGPBMCs). BMCs (0.5 Â 10 6 / ml) were cultured with immobilized anti-CD3 mAb (OKT3, 1 mg/ml, Ortho Biotech, Raritan, NJ, USA) and IL-15 (5 ng/ml, R&D Systems, Minneapolis, MN, USA) in RPMI-1640 with 5% of human AB serum in T25 culture flasks for 7 days, and purified CD94 þ cells were obtained by magnetic cell sorting (MACS) using magnetic microbeads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) as described previously. 5 Although there was no difference among the proportions of CD94/NKG2A-expressing T cells in normal PBMCs, DLIs and AGPBMCs before stimulation, the proportions of CD94/NKG2A-expressing T cells in CB were significantly lower before stimulation ( Table 1 ). The proportions of CD94/NKG2A-expressing T cells in the four different sources of BMCs after 7 days of stimulation with 
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Correspondence immobilized anti-CD3 mAb and IL-15 were increased to 30-50%, but there were no significant differences among the proportions of cells in the four sources. PBMCs, DLIs and AGPBMCs contained almost equal numbers but CB contained a significantly lower number of CD94/NKG2A-expressing T cells before stimulation. CD94/NKG2A-expressing CD8 þ T cells from the four kinds of BMCs were expanded by more than 100-fold after 7 days of culture. Moreover, a significantly greater number of CD94-expressing T cells was obtained from CB than from PBMCs. CD94-expressing cells were enriched by MACS, and more than 95% of these cells expressed CD94. Also, more than 90% of CD94-expressing cells coexpressed CD3 and more than 80% coexpressed CD8, whereas less than 5% of CD94-expressing cells coexpressed CD56 and CD16 (Figure 1a) . Therefore, these CD94-expressing cells contained less than 5% of NK cells and the majority of these cells were T cells. Also, these CD94 þ cells coexpressed NKG2D and CD244 but did not express CD158a, CD158b, NKB1, CD161 or NKp44 as described previously. 5 Furthermore, we found that almost all of the CD94-expressing T cells coexpressed LFA-1 and also ICAM-1 (Figure 1a) .
The cytolytic activities of purified CD94-expressing cells were tested against 51 Cr-labeled K562 cells, against primary leukemic cells derived from three patients with chronic myelogenous leukemia (CML) in the chronic phase, from one patient each with CML in myeloid blastic crisis (CML-BC), acute myelogenous leukemia (AML, M0), AML (M2), AML (M4), myelodysplastic syndrome (MDS) overt leukemia, acute lymphocytic leukemia (ALL, Ph1), adult T-cell leukemia (ATL) and leukemic change of Non-Hodgkin's lymphoma (NHL), and from two patients with T-lymphoblastic lymphoma/leukemia (LBL), and against autologous and allogeneic PHA blasts (5 Â 10
3 ) using standard 4-h 51 Cr release assays. Expanded and purified CD94-expressing cells attacked K562 cells and patients' leukemic cells to various degrees depending on the type of leukemia but did not attack autologous and allogeneic PHA blasts (Figure 1b) . Also, this killing activity of inhibitory NKR-expressing CD8 þ cells did not need prior sensitization. Anti-NKG2D mAb (50 mg/ ml, R&D Systems) suppressed the cytolytic activity of CD94-expressing cells against K562 cells and also patients' primary leukemic cells. Therefore, the cytolytic activity of CD94-expressing cells depends at least partially on NKG2D-activating NKR. 6 The expression of NKG2D ligands such as MIC and ULBP on leukemic cells has been reported. 7, 8 In this study, we analyzed the expression level of MICA on leukemic cells using mouse anti-human MICA mAb (20 mg/ml, mouse IgG2b, R&D Systems) as a first antibody and PE-labeled goat anti-mouse IgG2b (16 mg/ml, Santa Cruz Biotechnology) as a second antibody (Figure 1c Furthermore, anti-LFA-1 mAb (20 mg/ml, Immunotec, Marseilles, France) suppressed the cytolytic activity of CD94-expressing cells against K562 cells and also patients' primary leukemic cells much more effectively than did anti-NKG2D mAb (Figure 1d ). It has been reported that LFA-1 engages ICAM-1 as a dominant pathway of adhesion for cytotoxic lymphocytes. 9 Our data indicated that the cytolytic activity of inhibitory NKR-expressing cells also required adhesion through LFA-1.
Although the cytolytic activity of CD94-expressing cells depends on the expression of HLA class I molecules in roughly inverse proportion, 5 adhesion molecules and stimulatory NKR ligands such as MIC 10 In this study, we were able to expand CD94-expressing CD8 þ T cells from four different sources of BMCs (PBMCs, CB, DLIs and AGPBMCs). These expanded and purified CD94-expressing cells have both inhibitory receptors (NKG2A) and stimulatory receptors (NKG2D) as well as LFA-1 and ICAM-1. Therefore, it may be possible to expand CD94-expressing T cells from various sources of BMCs with cytolytic activity against both autologous and allogeneic primary leukemic cells for a new strategy of cell therapy.
